Clinical Trial: ECOG-ACRIN EA6174

ECOG-ACRIN EA6174

Status: Closed

NCT#03712605

STAMP: Surgically Treated Adjuvant Merkel cell carcinoma with Pembrolizumab, a Phase III Trial

Eligible for screening study DCP 001

EA6174 is closed to accrual, effective July 1, 2024.

The Montana Cancer Consortium (MCC) is an independent nonprofit organization whose mission is to bring state-of-the-art cancer care to Montana, Idaho and Wyoming through National Cancer Institute (NCI) sponsored clinical research.

Navigation

About Us

Contact Us

Copyright © Montana Cancer Consortium | All rights reserved